Table 2 Neoadjuvant therapy plus surgery compared to surgery alone for oesophageal cancer in relation to number of removed lymph nodes, expressed as rate ratios and 95% confidence intervals (CI).

From: Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer

Model

Patients Number

Surgery alone Rate ratio (95% CI)

Neoadjuvant therapy Rate ratio (95% CI)

Crude

1347

1.00 (reference)

0.77 (0.74–0.80)

Adjusteda

1307

1.00 (reference)

0.72 (0.69–0.75)

Adjustedb

1307

1.00 (reference)

0.75 (0.73–0.78)

Stratified by T-stage a

T0–1

319

1.00 (reference)

0.83 (0.77–0.89)

T2

296

1.00 (reference)

0.72 (0.66–0.77)

T3

578

1.00 (reference)

0.75 (0.71–0.80)

T4

92

1.00 (reference)

0.72 (0.60–0.87)

Tx

22

1.00 (reference)

0.48 (0.37–0.64)

Subgroup analysis of patients with neoadjuvant chemoradiotherapy versus surgery

Crude

1184

1.00 (reference)

0.73 (0.70–0.76)

Adjusteda

1156

1.00 (reference)

0.65 (0.62–0.68)

Adjustedb

1156

1.00 (reference)

0.68 (0.65–0.72)

Patients with neoadjuvant chemoradiotherapy versus surgery stratified by T-stage a

T0–1

274

1.00 (reference)

0.82 (0.75–0.89)

T2

248

1.00 (reference)

0.62 (0.56–0.68)

T3

531

1.00 (reference)

0.68 (0.62–0.74)

T4

83

1.00 (reference)

0.48 (0.35–0.67)

Tx

20

1.00 (reference)

0.42 (0.30–0.58)

  1. aAdjusted for age (per year), calendar year, Charlson’s Comorbidity Index, histology and surgeon volume.
  2. bAdjusted for age (per year), calendar year, Charlson’s Comorbidity Index, histology, surgeon volume and T-stage.
Back to article page